ArticleFrontiers in oncology2026
A Case Report: Gastric glomus tumor with RAD50 mutation and therapeutic advances.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric glomus tumor (GGT) is a rare mesenchymal neoplasm of the stomach that accounts for only 1% of gastrointestinal tumors and originates from glomus cells within the gastric wall. The exact etiology remains unclear, and due to nonspecific clinical manifestations, definitive diagnosis relies on imaging, pathology, and immunohistochemistry. We report a case of a 60-year-old female with a two-year history of unexplained upper abdominal burning pain. After undergoing abdominal CT, gastroscopy, pathology, and immunohistochemistry analyses, she was diagnosed with gastric glomus tumor complicated by hepatic metastasis. The patient subsequently received chemotherapy, transcatheter arterial embolization(TAE) for hemostasis, anti-infection treatment, blood transfusion, and symptomatic and supportive care at our hospital. Ultimately, the patient's overall survival was 21 months. This article presents the case and reviews the clinical presentation, pathological features, diagnosis, and treatment strategies for GGT to provide reference for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.